The use of β-blockers in children in ICU – results of the interactive survey, a brief overview and own opinion
https://doi.org/10.21292/2078-5658-2020-17-3-53-60
Abstract
Many hospitals use β-blockers in adult patients, however, their use in children has not yet been determined.
The objective: to collect data on the use of β-blockers in children in intensive care units (ICU).
Methods: an anonymous survey containing 17 questions regarding the use of β-blockers was distributed through social networks, messengers and email. The answers were compared with published data.
Results. 48 respondents provided their replies. The survey has shown that 66.7% of them use β-blockers in children while 33.3% do not. Differences in the use of β-blockers in general and pediatric ICUs are statistically insignificant. Most clinics (50%) use β-blockers in patients with congenital heart defects, followed by sepsis (18.5%). Esmolol (34.4%) is the first-line drug, followed by propranolol (31.3%). The doses ranges vary significantly (excluding esmolol). Basic monitoring and echocardiography (40.6%) are most often used to monitor the use of β-blockers.
Conclusion: The survey results have shown that in Russia, the use of β-blockers in children in ICU is very limited. It is necessary to conduct big randomized, multicenter, placebo-controlled studies that will determine the effectiveness of β-blockers in children in various clinical conditions.
About the Authors
D. K. Аzovskiy
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Dmitry K. Azovskiy - Doctor of Medical Sciences, Anesthesiologist and Emergency Physician
29, Bd. 5, Shmitovsky Rd., Moscow, 123317
Phone: +7 (499) 259‒38‒34
A. U. Lekmanov
G. N. Speransky Children Municipal Clinical Hospital no. 9
Russian Federation
Russian Federation
Andrey U. Lekmanov - Doctor of Medical Sciences, Professor
1, Ostrovityanova St., Moscow, 117997
Phone: +7 (499) 256‒11‒87
A. P. Shadchnev
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Anton P. Shadchnev - Doctor of Medical Sciences, Anesthesiologist and Emergency Physician
29, Bd. 5, Shmitovsky Rd., Moscow, 123317
Phone: +7 (499) 259‒38‒34
References
1. Аzovskiy D.K., Lekmanov А.U. The efficacy of the advanced monitoring in the acute phase of critical burns in children. Anesteziologiya i Reanimatologiya, 2019, no. 1, pp. 57-67. (In Russ.)
2. Аzovskiy D.K., Lekmanov А.U., Pilyutik S.F. Use of selective β1-atenolol blocker in children with severe thermal injury. Rossiyskiy. Vestnik detskoy khirurgii, anesteziologii i reanimatologii, 2016, no. 3 (6), pp. 73-80. (In Russ.)
3. Kozlov I.А. Pharmacological cardioprotection: what's new? Messenger of Anesthesiology and Resuscitation, 2019, no. 2 (16), pp. 57-66. (In Russ.)
4. Kucherov Yu.I., Zhirkova Yu.V., Rekhviashvili M.G. et al. Use of propanol for treating complicated hemangiomas in children. Pediatricheskaya Pharmocologiya, 2015, no. 4 (11), pp. 46-50. (In Russ.)
5. Agesen F.N., Weeke P.E., Tfelt-Hansen P. et al. Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology. Pharmacol. Res. Perspect., 2019, no. 4 (7), pp. 1-9.
6. Alabed S., Sabouni A., Dakhoul S. et al. Beta-blockers for congestive heart failure in children. Cochrane Database of Systematic Reviews, 2016, no. 4.
7. Alali A.S., Mukherjee K., McCredie V.A. et al. Beta-blockers and traumatic brain injury. Ann. Surgery, 2017, no. 6 (266), pp. 952-961.
8. Armstead W.M., Vavilala M.S. Propranolol protects cerebral autoregulation and reduces hippocampal neuronal cell death through inhibition of interleukin-6 upregulation after traumatic brain injury in pigs. Brit. J. Anaesthesia, 2019, July, pp. 1-8.
9. Berk J.L., Hagen J.F., Beyer W.H. et al. The treatment of endotoxin shock by beta adrenergic blockade. Ann. Surgery, 1969, no. 1 (169), pp. 74-81.
10. Black J.W., Stephenson J.S. Pharmacology of a new adrenergic beta-receptor-blocking compound (Nethalide). Lancet, 1962, no. 7251 (280), pp. 311-314.
11. Byington R.P. Beta-blocker heart attack trial: Design, methods, and baseline results. Control Clin. Trials, 1984, no. 4 (5), pp. 382-437.
12. Casiraghi A., Musazzi U.M., Franceschini I. et al. Is propranolol compounding from tablet safe for pediatric use? Results from an experimental test. Minerva Pediatrica, 2014, no. 66 (5), pp. 355-362.
13. Dakoutrou M., Alexopoulos A., Miligkos M. et al. Atenolol treatment for severe infantile hemangiomas: comparison with a propranolol group of our centre. J. Eur. Academ. Dermatol. Venereol., 2019, no. 5 (33), pp. e199–e200.
14. Davis A.L., Carcillo J.A., Aneja R.K. et al. American college of critical care medicine clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock. Crit. Care Med., 2017, no. 6 (45), pp. 1061-1093.
15. European Medicines Agency Hemangiol: EPAR, Product Information [Electronic resource]. URL: https://www.ema.europa.eu/en/medicines/human/EPAR/hemangiol#product-information-section (Accessed: 30.01.2020).
16. FDA Approved drug products with therapeutic equivalence evaluations. FDA, 39th-еd., U.S., Department of Health and Human Services, 2019, 1346 p.
17. Herndon D.N., Dasu M.R.K., Wolfe R.R. et al. Gene expression profiles and protein balance in skeletal muscle of burned children after β-adrenergic blockade. Am. J. Physiol.-Endocrinol. Metabolism, 2003, no. 4 (285), pp. E783–E789.
18. Herndon D.N., Hart D.W., Wolf S.E. et al. Reversal of catabolism by beta-blockade after severe burns. New Engl. J. Med., 2001, no. 17 (345), pp. 1223-1229.
19. Léauté-Labrèze C., Hoeger P., Mazereeuw-Hautier J. et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New Engl. J. Med., 2015, no. 8 (372), pp. 735-746.
20. Lichstein E., Morganroth J., Harrist R. et al. Effect of propranolol on ventricular arrhythmia. The beta-blocker heart attack trial experience. Circulation, 1983, no. 6, Pt. 2(67), pp. 10‒15.
21. Liu P., Wu Q., Tang Y. et al.The influence of esmolol on septic shock and sepsis: A meta-analysis of randomized controlled studies. Am. J. Emerg. Med., 2018, no. 3 (36), pp. 470-474.
22. Mahabir M., Ashbaugh A.R., Saumier D. et al. Propranolol’s impact on cognitive performance in post-traumatic stress disorder. J. Affective Disorders, 2016, no. 192, pp. 98-103.
23. Mohseni S., Talving P., Thelin E.P. et al. The Effect of β-blockade on Survival After Isolated Severe Traumatic Brain Injury. World J. Surgery, 2015, no. 8 (39), pp. 2076-2083.
24. Murry J.S., Hoang D.M., Barmparas G. et al. Prospective evaluation of early propranolol after traumatic brain injury. J. Surg. Research, 2016, no. 1 (200), pp. 221-226.
25. Nusmeier A., Hoeven J.G. van der, Lemson J. Cardiac output monitoring in pediatric patients. Expert. Rev. Med. Devices, 2010, no. 4 (7), pp. 503-517.
26. Ogrodowczyk M., Dettlaff K., Jelinska A. Beta-blockers: current state of knowledge and perspectives. Mini-Rev. Med. Chem., 2015, no. 1 (16), pp. 40-54.
27. Ojeda S., Blumenthal E., Stevens P. et al. The safety and efficacy of propranolol in reducing the hypermetabolic response in the pediatric burn population. J. Burn Care Res., 2018, no. 6 (39), pp. 963-969.
28. Prichard B.N.C., Gillam P.M.S. Treatment of hypertension with propranolol. BMJ, 1969, no. 5635 (1), pp. 7-16.
29. Romana-Souza B., Nascimento A.P., Monte-Alto-Costa A. Low-dose propranolol improves cutaneous wound healing of burn-injured rats. Plastic Reconstruc. Sur., 2008, no. 6 (122), pp. 1690-1699.
30. Stapleton M.P. Sir James black and propranolol the role of the basic sciences in the history of cardiovascular pharmacology. Texas Heart Institute J., 1997, no. 4 (24), pp. 336-342.
31. Stein C.M. β-Adrenergic Receptors Ed. D. Robertson, Academic Press, 2012, 59–61 p.
32. Williams F.N., Herndon D.N. Metabolic and endocrine considerations after burn injury. Clin. Plastic Surgery, 2017, no. 3 (44), pp. 541-553.
33. Williams F.N., Herndon D.N., Kulp G.A., et al. Propranolol decreases cardiac work in a dose-dependent manner in severely burned children. Surgery, 2011, no. 2 (149), pp. 231-239.
Review
For citations:
Аzovskiy D.K., Lekmanov A.U., Shadchnev A.P. The use of β-blockers in children in ICU – results of the interactive survey, a brief overview and own opinion. Messenger of ANESTHESIOLOGY AND RESUSCITATION. 2020;17(3):53-60. (In Russ.) https://doi.org/10.21292/2078-5658-2020-17-3-53-60
Email this article 